LI Jing, LIU Xin-yong, ZHAN Peng. Advances in human cytomegalovirus inhibitorsJ. Acta Pharmaceutica Sinica, 2020,55(4): 585-596. doi: 10.16438/j.0513-4870.2019-0729
Citation: LI Jing, LIU Xin-yong, ZHAN Peng. Advances in human cytomegalovirus inhibitorsJ. Acta Pharmaceutica Sinica, 2020,55(4): 585-596. doi: 10.16438/j.0513-4870.2019-0729

Advances in human cytomegalovirus inhibitors

  • At present, the anti-HCMV (human cytomegalovirus) drugs have some problems, such as moderate activity, poor bioavailability, which urge people to develop new anti-HCMV drugs. With the continuous study on the pathogenesis and biological characteristics of HCMV and the rapid development of new drug design strategies, new generation of anti-HCMV targets and drugs have been identified. This review selects the most representative research examples in recent years, and summarizes the new targets and research progress of anti-HCMV drugs from the perspective of medicinal chemistry.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return